Melanoma is a skin neoplasm that originates from malignant transformation of melanocytes.
It commonly occurs in the extremities of women and on trunk or head and neck in men.
Metastases are via lymphatic and hematogenous routes.
Bichakjian CK, Halpern AC, Johnson TM, et al. Guidelines of care for the management of primary cutaneous melanoma. J Am Acad Dermatol. 2011 Nov;65(5):1032-1047. http://pic2.cmt.com.cn/WebImages/Res/20130528/20130528_777961e9-aab4-432d-9349-860041357fe1.pdf. Accessed 19 Dec 2013. PMID: 21868127
Coit DG, Andtbacka R, Anker CJ et al. Melanoma, version 2.2013: featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2013;11:395-407. http://www.jnccn.org/content/11/4/395.full.pdf. Accessed 08 Jan 2014. PMID: 23584343
Dummer R, Guggenheim M, Arnold AW, et al. Updated Swiss guidelines for the treatment and follow-up of cutaneous melanoma. Swiss Med Wkly. 2011 Dec;141:w13320. doi: 10.4414/smw.2011.13320. Accessed 19 Dec 2013. PMID: 22180245
Dummer R, Hauschild A, Guggenheim M, et al. Cutaneous melanoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23(Suppl 7):vii86-vii91. http://annonc.oxfordjournals.org/content/23/suppl_7/vii86.full.pdf+html. Accessed 19 Dec 2013. PMID: 22997461
European Society for Medical Oncology. FDA approves pembrolizumab for advanced melanoma. ESMO. http://www.esmo.org/Oncology-News/FDA-Approves-Pembrolizumab-for-Advanced-Melanoma. 05 Sep 2014. Accessed 09 Sep 2014.
Fuerst M. Metastatic melanoma: immunotherapy with pembrolizumab induces durable responses. Oncology Times. 2014 Jul;36(13):35-36. doi: 10.1097/01.COT.0000452086.09862.55. Accessed 09 Sep 2014.
Melanoma. Medicines Complete. http://www.medicinescomplete.com/mc/martindale/current/1800-a4-737-j.htm#m1800-a4-814-h . 20 Aug 2010. Accessed 06 Jan 2014.
National Cancer Institute: PDQ® Melanoma Treatment. National Cancer Institute. http://www.cancer.gov/cancertopics/pdq/treatment/melanoma/HealthProfessional/page9/AllPages/Print. 11 Jul 2014. Accessed 01 Sep 2014.
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: melanoma. Version 4.2014. NCCN. http://www.nccn.org/professionals/physician_gls/pdf/melanoma.pdf. Accessed 28 Aug 2014.
Shenenberger DW. Cutaneous malignant melanoma: a primary care perspective. Am Fam Physician. 2012 Jan;85(2):161-168. http://www.aafp.org/afp/2012/0115/p161.html. Accessed 19 Dec 2013. PMID: 22335216
Sosman JA. Melanoma treatment; advanced or metastatic melanoma (beyond the basics). UpToDate. http://www.uptodate.com/contents/melanoma-treatment-advanced-or-metastatic-melanoma-beyond-the-basics. 30 May 2013. Accessed 19 Dec 2013.
Tan WW. Malignant melanoma treatment protocols. Medscape. http://emedicine.medscape.com/article/2006810-overview. 14 Jan 2014. Accessed 01 Sep 2014.
Thompson JF, Scolyer RA, Kefford RF. Melanoma, a management guide for GPs. Australian Family Physician. 2012 Jul;41(7):470-473. http://www.racgp.org.au/download/documents/AFP/2012/July/201207thompson.pdf. Accessed 20 Dec 2013.
Wells GL. Melanoma. The Merck Manual. http://www.merckmanuals.com/professional/dermatologic_disorders/cancers_of_the_skin/melanoma.html. May 2013. Accessed 20 Dec 2013.
Wong SL, Balch CM, Hurley P, et al. Sentinel lymph node biopsy for melanoma: American Society of Clinical Oncology and Society of Surgical Oncology joint clinical practice guideline. Journal of Clinical Oncology. 2012 Aug;30(23):2912-2917. http://jco.ascopubs.org/content/30/23/2912.full.pdf+html. Accessed 20 Dec 2013. PMID: 22778321
Dummer R, Hauschild A, Lindenblatt N, Pentheroudakis G, Keilholz U; ESMO Guidelines Committee. Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015 Sep;26(Suppl 5):v126-v132. https://annonc.oxfordjournals.org/content/26/suppl_5/v126.full.pdf. PMID: 26314774
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: melanoma. Version 2.2016. NCCN website. http://www.nccn.org/professionals/physician_gls/pdf/melanoma.pdf. 2016.
National Institute for Health and Care Excellence (NICE). Melanoma: assessment and management. NICE website. https://www.nice.org.uk/guidance/ng14/resources/melanoma-assessment-and-management-1837271430853. 2015.
Gershenwald JE, Scolyer RA, Hess KR, et al. Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017 Nov;67(6):472–492. doi: 10.3322/caac.21409. PMID: 29028110
Michielin O, van Akkooi ACJ, Ascierto PA, Dummer R, Keilholz U; ESMO Guidelines Committee. Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019 Dec;30(12):1884–1901. doi: 10.1093/annonc/mdz411. PMID: 31566661
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: Cutaneous melanoma. Version 1.2020. NCCN. https://www.nccn.org/. Dec 2019.
Swetter SM, Tsao H, Bichakjian CK, et al. Guidelines of care for the management of primary cutaneous melanoma. J Am Acad Dermatol. 2019 Jan;80(1):208-250. doi:10.1016/j.jaad.2018.08.055. PMID: 30392755
Dr. Hsu Li Yang, Dr. Tan Thuan Tong, Dr. Andrea Kwa,
08 Jan 2021
Antimicrobial resistance has become increasingly dire as the rapid emergence of drug resistance, especially gram-negative pathogens, has outpaced the development of new antibiotics. At a recent virtual symposium, Dr Hsu Li Yang, Vice Dean (Global Health) and Programme Leader (Infectious Diseases), NUS Saw Swee Hock School of Public Health, presented epidemiological data on multidrug-resistant (MDR) gram-negative bacteria (GNB) in Asia, while Dr Tan Thuan Tong, Head and Senior Consultant, Department of Infectious Diseases, Singapore General Hospital (SGH), focused on the role of ceftazidime-avibactam in MDR GNB infections. Dr Andrea Kwa, Assistant Director of Research, Department of Pharmacy, SGH, joined the panel in an interactive fireside chat, to discuss challenges, practical considerations, and solutions in MDR gram-negative infections. This Pfizer-sponsored symposium was chaired by Dr Ng Shin Yi, Head and Senior Consultant of Surgical Intensive Care, SGH.
Spending too much time sitting cannot be good for the body, and rising to one's feet breaks up such a behaviour and yields small, but meaningful, reductions in certain cardiovascular disease (CVD) risk factors, according to the results of a meta-analysis.